Examine how legitimate pharmaceutical export channels are exploited for illicit drug diversion. Suggest regulatory reforms.

Q. Examine how legitimate pharmaceutical export channels are exploited for illicit drug diversion. Suggest regulatory reforms. (15 marks, 250-350 words)

Tramadol — a synthetic opioid notified as a psychotropic substance under the NDPS Act, 1985 by notification of April 2018 [2] — shows how India's legitimate pharmaceutical export architecture can itself become the conduit for illicit diversion. The Central Bureau of Narcotics' "Operation Vajra" (July 2026), which seized 12 crore high-strength tablets (~30 metric tons) from a Delhi warehouse, illustrates the scale of the risk [1].

How export channels are exploited - False destination declaration: the consignment was ostensibly bound for Guinea-Bissau, but was apparently intended for diversion to Libya, using a weakly-regulated West African hub as a transshipment cover [1]. - Cover of lawful documentation: export of psychotropic substances requires a CBN No-Objection Certificate under the NDPS Rules, 1985 [3]; traffickers ride on licensed manufacture and genuine EXIM paperwork rather than evading it. - High-strength formulations for grey markets: 250 mg tablets, far above ordinary therapeutic use, were produced for destinations with negligible pharmacovigilance [1]. - Fragmented supply chain: sourcing, financing and warehousing were split across Bengaluru, Kochi and Delhi, so no single jurisdiction saw the full chain [1]. - Narco-conflict demand: Tramadol's reputation as a "fighter drug" among armed non-state actors sustains bulk demand in conflict theatres [1].

Regulatory reforms - End-use verification: make the importing country's import authorisation a mandatory precondition for the CBN NOC, digitally cross-checked with the destination regulator and INCB. - Track-and-trace: serialisation/barcoding of controlled formulations, with reconciliation of production, export and landing certificates. - Strength and volume caps: licence high-strength opioid formulations only against documented therapeutic demand, with red flags on sudden volume spikes. - Data integration: single-window linking of CBN licensing, Customs EDI, DGFT and DRI risk profiling for real-time consignment scoring. - Accountability and capacity: statutory due-diligence duties on exporters and customs brokers; strengthened CBN field staffing under Section 8(c) enforcement [3].

Operation Vajra confirms that intelligence-led enforcement works, but interception alone cannot substitute for prevention. Shifting from post-shipment detection to verified, traceable, end-use-linked licensing would let India protect its standing as the "pharmacy of the world" while honouring its obligations under the UN drug control conventions.

(~325 words)

Sources: 1. PIB — Central Bureau of Narcotics (CBN) India thwarts illegal trafficking of 12 crore Tramadol Hydrochloride "fighter drug" tablets under "Operation Vajra" — seizure quantity and weight, Delhi warehouse, Bengaluru/Kochi arrests, Guinea-Bissau declared vs Libya suspected destination, 250 mg strength, "fighter drug" tag 2. Gazette Notification S.O. 1761(E), 26 April 2018 (India Code) — inclusion of Tramadol in the list of psychotropic substances under the NDPS Act, 1985 3. The Narcotic Drugs and Psychotropic Substances Act, 1985 (India Code) and CBN — Acts & Rules — Section 8(c) export restriction and the CBN No-Objection Certificate requirement under the NDPS Rules